Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)
Purpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insufficientl...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2319304 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115341905035264 |
|---|---|
| author | Diego Orsini Giacomo Caldarola Annunziata Dattola Elena Campione Nicoletta Bernardini Pasquale Frascione Clara De Simone Antonio G. Richetta Marco Galluzzo Nevena Skroza Chiara Assorgi Emanuele Amore Gennaro M. Falco Ruslana Gaeta Shumak Fabio Artosi Giulia Maretti Concetta Potenza Luca Bianchi Giovanni Pellacani Ketty Peris Claudio Bonifati Dario Graceffa |
| author_facet | Diego Orsini Giacomo Caldarola Annunziata Dattola Elena Campione Nicoletta Bernardini Pasquale Frascione Clara De Simone Antonio G. Richetta Marco Galluzzo Nevena Skroza Chiara Assorgi Emanuele Amore Gennaro M. Falco Ruslana Gaeta Shumak Fabio Artosi Giulia Maretti Concetta Potenza Luca Bianchi Giovanni Pellacani Ketty Peris Claudio Bonifati Dario Graceffa |
| author_sort | Diego Orsini |
| collection | DOAJ |
| description | Purpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insufficiently explored. We conducted this real-life retrospective multicentric observational study to assess the effectiveness of tildrakizumab in elderly patients with moderate-to-severe psoriasis, with involvement of difficult-to-treat areas.Materials and methods: We enrolled forty-nine patients aged 65 years old or more (mean age 73.1 ± 6.0), all treated with tildrakizumab for at least 28 weeks. The effectiveness of tildrakizumab was assessed by Static Physician’s Global Assessment of Genitalia (sPGA-G), fingernail-PGA (f-PGA), palmoplantar PGA (pp-PGA), scalp-specific PGA (sc-PGA), and Psoriasis Area and Severity Index (PASI) scores.Results: Significant improvements in PASI scores were observed within 28 weeks of treatment, with 77.5%, 60%, and 45.2% of patients achieving PASI75, PASI90, and PASI100, respectively. The mean PASI decreased significantly from baseline (13.6 ± 9.9) to 1.3 ± 1.7 at week 28. More than 90% of patients had clear sPGA-G and pp-PGA scores and over 70% had clear f-PGA and sc-PGA scores after 28 weeks.Conclusions: Our findings suggest that tildrakizumab could be a valuable option for the treatment of elderly patients, including those with difficult-to-treat areas involvement. |
| format | Article |
| id | doaj-art-6ed0bed7541c4a9084145e7ddf8bf2a1 |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-6ed0bed7541c4a9084145e7ddf8bf2a12025-08-20T02:36:35ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2319304Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)Diego Orsini0Giacomo Caldarola1Annunziata Dattola2Elena Campione3Nicoletta Bernardini4Pasquale Frascione5Clara De Simone6Antonio G. Richetta7Marco Galluzzo8Nevena Skroza9Chiara Assorgi10Emanuele Amore11Gennaro M. Falco12Ruslana Gaeta Shumak13Fabio Artosi14Giulia Maretti15Concetta Potenza16Luca Bianchi17Giovanni Pellacani18Ketty Peris19Claudio Bonifati20Dario Graceffa21Clinical Dermatology Unit, IFO-San Gallicano Dermatological Institute-IRCCS, Rome, ItalyUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, ItalyUnit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyDermatology Unit “Daniele Innocenzi” ASL LATINA, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, ItalyOncologic and Preventive Dermatology Unit, IFO-San Gallicano Dermatological Institute-IRCCS, Rome, ItalyUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, ItalyUnit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyDermatology Unit “Daniele Innocenzi” ASL LATINA, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, ItalyClinical Dermatology Unit, IFO-San Gallicano Dermatological Institute-IRCCS, Rome, ItalyUnit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, ItalyUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyDermatology Unit “Daniele Innocenzi” ASL LATINA, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, ItalyDermatology Unit “Daniele Innocenzi” ASL LATINA, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyUnit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, ItalyUOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, ItalyClinical Dermatology Unit, IFO-San Gallicano Dermatological Institute-IRCCS, Rome, ItalyClinical Dermatology Unit, IFO-San Gallicano Dermatological Institute-IRCCS, Rome, ItalyPurpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insufficiently explored. We conducted this real-life retrospective multicentric observational study to assess the effectiveness of tildrakizumab in elderly patients with moderate-to-severe psoriasis, with involvement of difficult-to-treat areas.Materials and methods: We enrolled forty-nine patients aged 65 years old or more (mean age 73.1 ± 6.0), all treated with tildrakizumab for at least 28 weeks. The effectiveness of tildrakizumab was assessed by Static Physician’s Global Assessment of Genitalia (sPGA-G), fingernail-PGA (f-PGA), palmoplantar PGA (pp-PGA), scalp-specific PGA (sc-PGA), and Psoriasis Area and Severity Index (PASI) scores.Results: Significant improvements in PASI scores were observed within 28 weeks of treatment, with 77.5%, 60%, and 45.2% of patients achieving PASI75, PASI90, and PASI100, respectively. The mean PASI decreased significantly from baseline (13.6 ± 9.9) to 1.3 ± 1.7 at week 28. More than 90% of patients had clear sPGA-G and pp-PGA scores and over 70% had clear f-PGA and sc-PGA scores after 28 weeks.Conclusions: Our findings suggest that tildrakizumab could be a valuable option for the treatment of elderly patients, including those with difficult-to-treat areas involvement.https://www.tandfonline.com/doi/10.1080/09546634.2024.2319304Tildrakizumabimmunomodulatory therapiesbiologicspsoriasispsoriasis treatmentanti-IL-23-biologics |
| spellingShingle | Diego Orsini Giacomo Caldarola Annunziata Dattola Elena Campione Nicoletta Bernardini Pasquale Frascione Clara De Simone Antonio G. Richetta Marco Galluzzo Nevena Skroza Chiara Assorgi Emanuele Amore Gennaro M. Falco Ruslana Gaeta Shumak Fabio Artosi Giulia Maretti Concetta Potenza Luca Bianchi Giovanni Pellacani Ketty Peris Claudio Bonifati Dario Graceffa Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) Journal of Dermatological Treatment Tildrakizumab immunomodulatory therapies biologics psoriasis psoriasis treatment anti-IL-23-biologics |
| title | Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) |
| title_full | Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) |
| title_fullStr | Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) |
| title_full_unstemmed | Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) |
| title_short | Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) |
| title_sort | efficacy and safety of tildrakizumab in elderly patients real world multicenter study ester study |
| topic | Tildrakizumab immunomodulatory therapies biologics psoriasis psoriasis treatment anti-IL-23-biologics |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2319304 |
| work_keys_str_mv | AT diegoorsini efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT giacomocaldarola efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT annunziatadattola efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT elenacampione efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT nicolettabernardini efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT pasqualefrascione efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT claradesimone efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT antoniogrichetta efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT marcogalluzzo efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT nevenaskroza efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT chiaraassorgi efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT emanueleamore efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT gennaromfalco efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT ruslanagaetashumak efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT fabioartosi efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT giuliamaretti efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT concettapotenza efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT lucabianchi efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT giovannipellacani efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT kettyperis efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT claudiobonifati efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy AT dariograceffa efficacyandsafetyoftildrakizumabinelderlypatientsrealworldmulticenterstudyesterstudy |